THE NEED

Lung cancer remains a leading cause of death from cancer globally, due to its high incidence and late-stage diagnosis. Most patients are currently diagnosed with late-stage cancer, though research has shown 5-year survival rates are up to 10 times greater when disease is detected early. Annual imaging (low-dose CT scans) is recommended for screening individuals with highest risk, but less than 10% of those eligible adhere to guidelines². Delivering an effective screening option for high risk individuals could increase compliance for imaging and drive more patients to treatment when it can have the greatest chance of having a long-term benefit.

OUR SOLUTION

Lung EpiCheck is a simple blood test that detects lung tumor DNA circulating in the blood. The test detects subtle disease-specific changes in DNA methylation markers. Lung EpiCheck is an objective molecular test meaning that it does not rely on human interpretation. The result is a clear positive/negative result, with an additional numerical result between 0-100.